Menopause Hormone Therapy: Benefits, Risks & Questions

“I’ve heard hormone therapy can help with hot flashes, but I’ve also heard it’s risky. I don’t know what to believe, and I don’t want to make the wrong decision.”

If this is where you are, you are asking exactly the right question. And you are far from alone in feeling caught between conflicting information.

Hormone therapy is one of the most researched treatments in women’s health. It is also one of the most misunderstood. Much of the confusion traces back to a single, widely publicized study from more than two decades ago, one that has since been re-examined and substantially reframed by subsequent research. Understandably, the fear it created has lingered far longer than the nuance that followed.

You deserve a clear, honest, evidence-based explanation. Not headlines, not fear, and not a sales pitch. This article walks through what hormone therapy is, what the current evidence says about its benefits and risks, who it may be appropriate for, and the specific questions worth bringing to a provider before you decide anything.

If you are ready for that conversation now, you can book a hormone therapy consultation at hervitalwellness.com.

Key takeaways

Menopause hormone therapy remains the most effective treatment for moderate to severe hot flashes and night sweats, according to The Menopause Society and multiple international guidelines.
The benefit-risk profile is most favorable for healthy, symptomatic women under 60 or within 10 years of menopause onset, and varies by hormone type, dose, and delivery method.
Estrogen-only therapy and combined estrogen-progestogen therapy carry different risk profiles, particularly regarding breast cancer and blood clots.
Transdermal estrogen (patches, gels) may carry a lower risk of blood clots compared to oral estrogen.
Compounded “bioidentical” hormones are not FDA-regulated and lack the same safety and efficacy data as approved products.
This is a highly individualized decision best made in partnership with a provider who has time for your full history and your questions.

What is menopause hormone therapy?

Menopausal hormone therapy (often called HRT or MHT) refers to medications that replace hormones, primarily estrogen, sometimes combined with progesterone, and in some cases testosterone, that decline during the menopause transition. Providers most commonly use it to address symptoms like hot flashes, night sweats, vaginal dryness, and sleep disruption. It is also associated with certain longer-term health considerations, including bone health. [1-2]

Hormone therapy is not one single treatment. It comes in multiple forms (pills, patches, gels, sprays, and vaginal preparations) and multiple hormone combinations, each suited to different symptoms, health histories, and goals. [3] As a result, a one-size-fits-all answer about hormone therapy (“it’s safe” or “it’s risky”) misses the point. The right answer depends on the specific formulation, dose, delivery method, and the individual woman receiving treatment.

Systemic vs. local: an important distinction

Systemic estrogen (pills, patches, gels, sprays) addresses whole-body symptoms like hot flashes and night sweats. In contrast, local vaginal estrogen addresses vaginal and urinary symptoms with minimal systemic absorption. [3] These serve different purposes and are not interchangeable. Current evidence supports the safety of low-dose vaginal estrogen for genitourinary syndrome of menopause, including in some cancer survivors. [2]

Why this matters during midlife

As estrogen and progesterone decline during perimenopause and menopause, many women experience symptoms that meaningfully affect quality of life. Hot flashes, night sweats, sleep disruption, vaginal dryness, and mood changes are among the most common. For some women, these symptoms are manageable with lifestyle strategies alone. For others, they are significant enough that additional options are worth exploring.

Several factors shape whether hormone therapy might be a reasonable option to discuss: the severity and type of your symptoms, your personal and family health history (including any history of certain cancers, blood clots, or cardiovascular disease), your age and how many years have passed since your last period, and your personal goals and comfort with the evidence. [1][3]

For more on recognizing whether your symptoms may be related to the menopause transition, see our related article.

What does the evidence show?

This is where nuance matters most. The evidence on menopause hormone therapy has evolved considerably over the past two decades, and understanding that evolution is essential to making an informed decision.

The WHI study: what happened and what we know now

The original 2002 Women’s Health Initiative (WHI) study raised concerns about breast cancer, cardiovascular events, and blood clots associated with a specific hormone therapy regimen (oral conjugated equine estrogens plus medroxyprogesterone acetate), studied in a population that was, on average, older than the women who most commonly seek treatment for menopause symptoms today. [4-5]

Subsequent re-analyses have clarified several important points. Cardiovascular outcomes are strongly influenced by timing: initiation before age 60 or within 10 years of menopause may confer benefit, while delayed initiation (age 65 and older) increases risks of coronary events and stroke, supporting the “window of opportunity” hypothesis. [6] A 2025 secondary analysis of the WHI trials confirmed that among younger postmenopausal women aged 50 to 59, both estrogen alone and combined therapy reduced vasomotor symptoms without significantly affecting atherosclerotic cardiovascular disease risk. [7]

Benefits

Current guidance from The Menopause Society states that for healthy, symptomatic women who are within 10 years of menopause onset or under age 60, hormone therapy has one of the more favorable benefit-risk profiles among treatment options. [1] Specifically:

It is the most effective treatment for moderate to severe hot flashes and night sweats, reducing frequency by approximately two to four fewer episodes per day compared to placebo. [1][8]
It prevents bone loss and reduces fracture risk. [1][6]
It may help with vaginal dryness, sleep disruption connected to vasomotor symptoms, and some aspects of quality of life. [1][3]
A consistent finding across analyses suggests a possible 30% decrease in all-cause mortality when initiated early in menopause, though hormone therapy is not recommended solely for disease prevention. [9]

Risks

The risk profile varies considerably by age at initiation, time since menopause, hormone type, dose, and delivery method. [1-2][6] Key considerations include:

Venous thromboembolism (blood clots): Oral estrogen increases the risk, while transdermal estrogen (patches, gels) does not appear to carry the same risk. A large UK nested case-control study of over 80,000 women with VTE found that transdermal preparations were not associated with increased risk of blood clots, while oral preparations were. [10-12]
Stroke: Both oral estrogen-only and combined therapy have been associated with a modestly increased risk of stroke in the WHI. However, absolute excess risks are small in younger women closer to menopause. [3-4][13]
Breast cancer: This is where the distinction between estrogen-only and combined therapy matters most. Combined estrogen-progestogen therapy probably increases breast cancer risk, while estrogen-only therapy (for women without a uterus) has not shown the same increase and may even be associated with a reduction in breast cancer incidence and mortality over long-term follow-up. The choice of progestogen also appears to matter, with observational evidence suggesting that micronized progesterone and dydrogesterone may carry a more favorable breast cancer risk profile than some synthetic progestins. [6][14-18]
Cardiovascular disease: Neither estrogen alone nor combined therapy significantly increases the risk of coronary heart disease in younger women near menopause. However, initiating hormone therapy after age 70 significantly increases cardiovascular risk. [4][7]

What we still don’t know

Research on long-term outcomes, individualized risk prediction, and specific formulations continues to evolve. In particular, most large randomized trial data come from the WHI, which studied specific formulations (conjugated equine estrogens and medroxyprogesterone acetate) that differ from many of the formulations commonly prescribed today. [2][4] This is an active area of research, and guidance continues to be refined as new evidence emerges.

What every woman should know

Myth vs. fact

Myth	Fact
Hormone therapy is dangerous for all women	The benefit-risk profile is most favorable for healthy, symptomatic women under 60 or within 10 years of menopause, and varies by formulation [1-2]
The WHI proved hormone therapy causes heart attacks	Subsequent analyses show no significant increase in coronary heart disease risk in younger women near menopause [3-4]
All hormone therapy carries the same breast cancer risk	Estrogen-only therapy has not shown the same breast cancer increase as combined therapy, and may even reduce risk over long-term follow-up [5-7]
“Natural” or “bioidentical” hormones are automatically safer	Compounded bioidentical hormones are not FDA-regulated and lack the same safety and efficacy data as approved products [8-9]
Hormone therapy is the only option for hot flashes	FDA-approved non-hormonal options exist, including fezolinetant and certain SSRIs/SNRIs [10-11]
You should stop hormone therapy after a set number of years	There is no arbitrary age-based stopping rule; duration should be individualized based on ongoing symptoms and benefit-risk assessment [1, 6]

Key points to remember

Hormone therapy is not a single treatment. The type, dose, and delivery method all affect the benefit-risk profile.
The fear generated by early WHI headlines does not reflect the more nuanced picture that subsequent research has provided.
For many healthy, symptomatic women closer to the start of menopause, hormone therapy may be a reasonable and evidence-supported option worth discussing.
Hormone therapy is not appropriate for every woman, and that is a legitimate, individualized medical determination, not a judgment about you.
This is a decision that should be made in partnership with a provider who has time to review your full history, not from a headline, a social media post, or a friend’s experience alone.

Evidence-based treatment options

If you are considering hormone therapy, a thoughtful, individualized process typically includes the following steps.

Step 1: A full history review

This includes your personal and family medical history, current symptoms, prior treatments, and any risk factors that might affect the benefit-risk calculation for you specifically. Understanding what your hormone labs mean can be a helpful part of this process, though hormone therapy decisions are based on symptoms and clinical context, not lab values alone.

Because thyroid conditions can mimic some menopause symptoms, ruling out overlapping conditions is also important. Our article on [Thyroid Problems or Perimenopause?] explores this further.

Step 2: Understanding your hormone therapy options

Estrogen therapy

Systemic estrogen is the primary treatment for vasomotor symptoms. It comes in oral (pills), transdermal (patches, gels, sprays), and vaginal forms. [3] Research suggests transdermal estrogen may carry a lower risk of blood clots compared to oral estrogen, which is one of several factors worth discussing based on your individual risk profile. [10-12] A 2026 narrative review in Pharmacotherapy confirmed that contemporary data support the preferential use of transdermal estradiol due to its lower risk of venous thromboembolism. [2]

Progesterone

Progesterone is typically recommended alongside estrogen for women who still have a uterus, to protect the uterine lining from hyperplasia and cancer. [3] The type of progesterone matters: oral micronized progesterone is generally favored over synthetic progestins when endometrial protection is required, based on its potentially more favorable breast cancer risk profile. [2][18][22]

Testosterone

Testosterone therapy is a more limited, evolving area of research. An international consensus position statement concluded that transdermal testosterone, in doses that approximate premenopausal levels, exerts a beneficial effect on sexual function in postmenopausal women with hypoactive sexual desire disorder. [23] However, testosterone is not FDA-approved for women in the United States, long-term safety data are lacking, and compounded testosterone formulations carry additional concerns about uncertain absorption and dosing. [24-25] Accordingly, this is a conversation that requires careful, individualized evaluation.

Non-hormonal alternatives

For women who are not candidates for hormone therapy, or who prefer not to use it, evidence-supported non-hormonal options exist.

Fezolinetant, a neurokinin 3 receptor antagonist approved by the FDA in 2023, reduces moderate to severe hot flash frequency by approximately 20 to 25% beyond placebo. [20-21]
Low-dose paroxetine (7.5 mg) is the only SSRI FDA-approved for vasomotor symptoms, with other SSRIs and SNRIs used off-label. [20]
Elinzanetant, a dual neurokinin receptor antagonist, received FDA approval in 2025 for moderate to severe vasomotor symptoms. [26]
Cognitive behavioral therapy and clinical hypnosis have also shown benefit in clinical trials. [20]

It is worth noting that while these options are valuable, a 2023 review by the US Institute for Clinical and Economic Review concluded that fezolinetant was less effective than hormone therapy for vasomotor symptoms, and that hormone therapy may provide additional benefits for sleep, vaginal dryness, and fracture prevention. [8]

Step 3: Choosing a delivery method thoughtfully

The delivery method is not just a matter of convenience. As noted above, transdermal estrogen may carry a lower risk of blood clots compared to oral estrogen. [10-11] ACOG has specifically noted that gynecologists should take into consideration the possible thrombosis-sparing properties of transdermal forms of estrogen therapy. [27] For women with risk factors for venous thromboembolism, transdermal estrogen appears to confer no increased risk. [28]

Step 4: Monitoring and follow-up

Hormone therapy is not typically a “start and forget” treatment. Regular follow-up allows your provider to assess how you are responding, adjust dosing if needed, and reassess the ongoing benefit-risk balance over time. [1-2] The Menopause Society advises that longer durations of therapy should involve shared decision-making and periodic reevaluation. [1]

A note on compounded “bioidentical” hormones

This is an area where clarity matters. The term “bioidentical” simply means the hormone is chemically identical to what the body produces. Several FDA-approved hormone therapies are bioidentical, including estradiol patches and oral micronized progesterone. [3][19]

However, compounded preparations of bioidentical hormones are not FDA-approved and should be approached with caution. A 2023 JAMA review noted that compounded preparations have not been evaluated for safety or effectiveness and are not monitored for quality. [3] ACOG’s 2023 clinical consensus states that compounded bioidentical menopausal hormone therapy should not be prescribed routinely when FDA-approved formulations exist. [19] The National Academies of Sciences concluded that most marketing claims about the safety and effectiveness of compounded preparations are not supported by properly controlled studies. [3][29]

If you are currently using or considering compounded hormones, this is worth discussing with your provider so you can make a fully informed decision.

If you are weighing these options and want a personalized plan, book a consultation at hervitalwellness.com.

Who should not take hormone therapy

Hormone therapy is not appropriate for every woman. Recognized contraindications include: [8][30]

History of hormone-sensitive breast cancer or estrogen-sensitive endometrial cancer
History of venous thromboembolism or pulmonary embolism (particularly unprovoked events or high-risk thrombophilia)
Active or recent arterial thromboembolic disease (angina, myocardial infarction, stroke, or transient ischemic attack)
Prior atherosclerotic cardiovascular disease
Severe active liver disease
Unexplained vaginal bleeding

In addition, The Menopause Society cautions against starting hormone therapy after age 60 or beyond 10 years since menopause, when the benefit-risk ratio appears less favorable. [1] A 2025 WHI secondary analysis specifically underscored the need to avoid hormone therapy in women after age 70. [7]

For women with these contraindications, non-hormonal treatment options (discussed above) may be appropriate alternatives worth exploring.

Questions to ask before starting hormone therapy

Bringing these questions to your consultation can help you feel confident in your decision, whatever you choose:

Based on my personal and family history, what does my individual benefit-risk profile look like?
Which type, dose, and delivery method would you recommend for my specific symptoms, and why?
Should I use a patch or gel instead of a pill, given my risk factors?
How soon might I notice a difference, and how will we know if it’s working?
What follow-up and monitoring will this treatment involve?
Are there specific warning signs I should watch for?
What would change our plan or make this treatment no longer appropriate for me?
What non-hormonal options exist if this is not the right fit for me?
Am I a candidate for estrogen-only therapy, or do I need combined therapy?
What is the difference between FDA-approved bioidentical hormones and compounded preparations?

A provider who welcomes these questions, and takes the time to answer them fully, is doing exactly what this decision deserves.

When to see a provider

Considering hormone therapy is itself often the reason women seek an evaluation. However, certain situations make that conversation more time-sensitive:

Hot flashes or night sweats that are significantly affecting your sleep, work, or daily life
Vaginal dryness or urinary symptoms that are affecting comfort or intimacy
A history of early menopause or premature ovarian insufficiency, where hormone therapy is often recommended for longer-term health considerations, including bone and cardiovascular health
Uncertainty about whether your current symptoms and history make you a reasonable candidate
A desire for a second opinion if a prior provider dismissed the option without a full discussion of your individual circumstances

When to see a specialist right away

Some symptoms warrant prompt evaluation beyond a general menopause consultation:

New breast lump or abnormal mammogram while on hormone therapy (breast specialist referral)
Sudden leg swelling, pain, or shortness of breath, which could indicate a blood clot (emergency evaluation)
Chest pain or new neurological symptoms such as sudden weakness, vision changes, or difficulty speaking (emergency evaluation)
Unexplained vaginal bleeding after menopause, whether or not you are on hormone therapy (gynecology evaluation)

Checklist to bring to your consultation

Your personal and family medical history, including any history of breast cancer, blood clots, heart disease, or stroke
A list of current medications, supplements, and doses
A description of your current symptoms: type, severity, frequency, and how long they have been present
Your most recent mammogram and any relevant lab results
Any prior experience with hormone therapy or other menopause treatments
Your questions (the list above is a good starting point)
Your personal goals and priorities for treatment

Looking at the whole picture

Hormone therapy is neither a miracle nor something to fear reflexively. It is one evidence-based option among several, and whether it is right for you depends on your full history, your specific symptoms, and your personal goals and values. This is exactly the kind of decision that benefits from an unhurried conversation, not a quick prescription or a blanket “no.”

You deserve a provider who will walk through the actual evidence with you, answer every question you bring, and help you make a decision you feel genuinely informed about. Menopause hormone therapy, when appropriate, can meaningfully improve quality of life. And when it is not the right fit, there are other evidence-based paths forward.

If you are weighing whether hormone therapy might be right for you, book a hormone therapy consultation at hervitalwellness.com to have this conversation in full.

Frequently asked questions

Is hormone therapy safe?

There is no single yes-or-no answer, because safety depends on the specific type, dose, delivery method, your age, time since menopause, and your personal health history. For healthy, symptomatic women under 60 or within 10 years of menopause onset, current guidelines from The Menopause Society indicate that the benefit-risk ratio is favorable for treating bothersome vasomotor symptoms. [1] The conversation changes for women with certain contraindications or those further from menopause.

Does hormone therapy cause breast cancer?

The relationship between hormone therapy and breast cancer depends on the type of therapy. Combined estrogen-progestogen therapy probably increases breast cancer risk modestly, while estrogen-only therapy (for women without a uterus) has not shown the same increase and may even reduce breast cancer incidence and mortality over long-term follow-up in the WHI trials. [14-16] The choice of progestogen also appears to matter, with observational data suggesting micronized progesterone may carry a more favorable profile than some synthetic progestins. [17-18]

What is the “window of opportunity” for starting hormone therapy?

This refers to the finding that hormone therapy appears to have the most favorable benefit-risk profile when started within 10 years of menopause onset or before age 60. [1][6] Starting later, particularly after age 70, has been associated with increased cardiovascular risk. [7] This timing effect is one of the most important factors in the decision.

What is the difference between bioidentical and regular hormone therapy?

“Bioidentical” means the hormone is chemically identical to what the body produces. Several FDA-approved hormone therapies are bioidentical, including estradiol patches and oral micronized progesterone. [3][19] Compounded bioidentical preparations, by contrast, are not FDA-approved, lack rigorous quality control, and have not been evaluated for safety or effectiveness in the same way. [19][29] ACOG recommends FDA-approved formulations over compounded preparations when available.

Is a patch better than a pill?

For some women, yes. Research consistently shows that transdermal estrogen (patches, gels) does not appear to increase the risk of blood clots, while oral estrogen does. [10-12] ACOG has noted that gynecologists should consider the thrombosis-sparing properties of transdermal estrogen. [27] Consequently, transdermal delivery may be particularly worth considering for women with risk factors for blood clots.

Can I take hormone therapy if I have a family history of breast cancer?

A family history of breast cancer does not automatically rule out hormone therapy, but it does change the conversation. The decision requires a careful, individualized assessment of your specific risk factors, the type of hormone therapy being considered, and your symptom burden. [1][3] This is exactly the kind of nuanced discussion that benefits from an unhurried consultation.

What are the non-hormonal alternatives for hot flashes?

FDA-approved non-hormonal options include fezolinetant (a neurokinin 3 receptor antagonist), elinzanetant (a dual neurokinin receptor antagonist), and low-dose paroxetine. [20][26] Other SSRIs, SNRIs, gabapentin, clonidine, and oxybutynin are used off-label with varying levels of evidence. [20] Cognitive behavioral therapy and clinical hypnosis have also shown benefit. [20] These options are particularly valuable for women with contraindications to hormone therapy.

How long can I stay on hormone therapy?

There is no arbitrary time limit. The Menopause Society advises that longer durations of therapy should be for documented indications such as persistent vasomotor symptoms, with shared decision-making and periodic reevaluation of the benefits and risks of continuing. [1][15] The decision to continue, reduce, or stop should be individualized, not based on a fixed number of years.

Will my symptoms come back if I stop hormone therapy?

Stopping hormone therapy commonly leads to resurgent vasomotor symptoms in up to 50% of women, and neither stopping abruptly nor tapering gradually has been shown to prevent this resurgence. [8] Whether this reflects ongoing menopausal symptoms or a withdrawal effect is not entirely clear. This is another reason why the decision about duration should be individualized.

Does hormone therapy help with brain fog during menopause?

Research on hormone therapy and cognition is mixed. Hormone therapy may improve memory and concentration in women taking it for vasomotor symptoms, but it is unlikely to have a cognitive effect in women without vasomotor symptoms. [8] Importantly, early initiation has no adverse effect on cognitive function, whereas late initiation (after age 65) has been associated with increased dementia risk. [6][13] For more on cognitive changes during the menopause transition, see our article on [menopause brain fog].

Should I get my hormone levels tested before starting?

Hormone levels are not typically required to diagnose menopause or to decide whether hormone therapy is appropriate. The decision is based primarily on your symptoms, age, time since menopause, and health history. [3] That said, certain lab tests (thyroid function, for example) can help rule out other conditions that mimic menopause symptoms. Our article on what your hormone labs mean discusses this in more detail.

Is testosterone therapy right for me?

Testosterone therapy may be considered for women with distressing low sexual desire (hypoactive sexual desire disorder) who have not responded to other approaches. [23-25] It is not FDA-approved for women in the United States. An international consensus statement recommends against the use of compounded testosterone preparations and advises regular monitoring of testosterone levels and signs of androgen excess when testosterone is prescribed. [23]

(Telehealth appointments are currently available for patients located in Arizona and New York.)

Schedule a Consultation

This information is educational and not a substitute for personalized medical care.

References

The Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. PMID: 35797481.
Manson JE, Crandall CJ, Rossouw JE, et al. The Women’s Health Initiative Randomized Trials and Clinical Practice: A Review. JAMA. 2024;331(20):1748-1760. PMID: 38691368.
Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women’s Health Initiative Randomized Trials. JAMA. 2013;310(13):1353-1368.
Lambrinoudaki I, Armeni E, Milli N, Anagnostis P. Then and Now: What We Have Learned From the WHI. Journal of Clinical Endocrinology and Metabolism. 2026;111(4):e974-e994. PMID: 41379766.
Rossouw JE, Aragaki AK, Manson JE, et al. Menopausal Hormone Therapy and Cardiovascular Diseases in Women With Vasomotor Symptoms. JAMA Internal Medicine. 2025.
Finks SW, Cieri-Hutcherson NE, Vernon V, McBane SE. Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence. Pharmacotherapy. 2026. PMID: 42304170.
Crandall CJ, Mehta JM, Manson JE. Management of Menopausal Symptoms: A Review. JAMA. 2023;329(5):405-420.
Genazzani AR, Monteleone P, Giannini A, Simoncini T. Hormone Therapy in the Postmenopausal Years: Considering Benefits and Risks in Clinical Practice. Human Reproduction Update. 2021;27(6):1115-1150. PMID: 34432008.
Lobo RA, Gompel A. Management of Menopause: A View Towards Prevention. Lancet Diabetes & Endocrinology. 2022;10(6):457-470.
Hickey M, LaCroix AZ, Doust J, et al. An Empowerment Model for Managing Menopause. Lancet. 2024;403(10430):947-957.
Vinogradova Y, Coupland C, Hippisley-Cox J. Use of Hormone Replacement Therapy and Risk of Venous Thromboembolism: Nested Case-Control Studies Using the QResearch and CPRD Databases. BMJ. 2019;364:k4810. PMID: 30626577.
Mohammed K, Abu Dabrh AM, Benkhadra K, et al. Oral vs Transdermal Estrogen Therapy and Vascular Events: A Systematic Review and Meta-Analysis. Journal of Clinical Endocrinology and Metabolism. 2015;100(11):4012-4020. PMID: 26544651.
Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone Replacement Therapy and Risk of Venous Thromboembolism in Postmenopausal Women: Systematic Review and Meta-Analysis. BMJ. 2008;336(7655):1227-1231. PMID: 18495631.
Hicks A, Robson D, Tellis B, et al. Safety of Menopause Hormone Therapy in Postmenopausal Women at Higher Risk of Venous Thromboembolism: A Systematic Review. Climacteric. 2025. PMID: 40488293.
Committee on Gynecologic Practice (ACOG). Postmenopausal Estrogen Therapy Route of Administration and Risk of Venous Thromboembolism. Committee Opinion. 2013.
Collaborative Group on Hormonal Factors in Breast Cancer. Type and Timing of Menopausal Hormone Therapy and Breast Cancer Risk: Individual Participant Meta-Analysis of the Worldwide Epidemiological Evidence. Lancet. 2019;394(10204):1159-1168.
Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-Term Follow-Up of the Women’s Health Initiative Randomized Clinical Trials. JAMA. 2020;324(4):369-380.
Wu Q, Shen L, Hu S, et al. Relationship Between Menopausal Hormone Therapy and Incidence Risk of Breast Cancer: Systematic Review and Meta-Analysis. Annals of Medicine. 2026. PMID: 41808362.
Bofill Rodriguez M, Yong LN, Mirkov S, et al. Long-term Hormone Therapy for Perimenopausal and Postmenopausal Women. Cochrane Database of Systematic Reviews. 2025.
Gompel A, Simcock R. Menopausal Hormone Treatment and Breast Cancer. Lancet Diabetes & Endocrinology. 2026.
Bollam R, Karam J, Shufelt C, Faubion SS. Menopausal Hormone Therapy and Breast Cancer: Balancing Risks and Benefits. Maturitas. 2026. PMID: 41740564.
Committee on Clinical Consensus–Gynecology (ACOG). Compounded Bioidentical Menopausal Hormone Therapy. Clinical Consensus. 2023.
Stuenkel CA, Manson JE. Compounded Bioidentical Hormone Therapy: The National Academies Weigh In. JAMA Internal Medicine. 2021;181(3):305-306.
US Preventive Services Task Force. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: Recommendation Statement. JAMA. 2022;328(17):1740-1746.
Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women